A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) ligand in men with suspected prostate cancer recurrence based on elevated Prostate-specific antigen (PSA) following prior therapy.
|Treatment||rhPSMA-7.3 (18F) Injection|
|Clinical Study Identifier||NCT04186845|
|Sponsor||Blue Earth Diagnostics|
|Last Modified on||17 January 2021|
Select a piece of text and start making personal notes.
Congrats! You have your own personal workspace now.